Clinical trial
The Effect Of Oral Ibandronate In Male Osteoporosis
NCT00397839 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00397839 |
|---|---|
| Title | The Effect Of Oral Ibandronate In Male Osteoporosis |
| Official title | A Parallel, Placebo-controlled, Randomized (2:1) Double-blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-monthly Versus Placebo on LS BMD in Men With Osteoporosis |
| Acronym | STRONG |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Male Osteoporosis |
| Intervention type | Drug |
| Interventions | Ibandronate, placebo |
| Enrollment | 135 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Nov 10, 2006 |
| Last update posted | Dec 21, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: